Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OvaRex (oregovomab) Consolidation for Ovarian Cancer
NCT00034372Phase 2Terminated
- Sponsor
- Unither Pharmaceuticals
- Start
- Sep 2000
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of oregovomab in ovarian cancer (3 arms), sponsored by Unither Pharmaceuticals. Primary endpoint: Time to disease relapse at 2 years. Started Sep 2000; status: terminated.
02
Drugs
oregovomab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00034372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034372.